275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2020. Parexel International Corporation.
Regulatory Consulting
Start your regulatory journey on the right foot.
The final stretch of regulatory submissions can seem murky – especially when that path takes you through the requirements of multiple countries. Every one of our 1000+ regulatory consultants across 110 countries share a deep understanding of intricate regulatory requirements and a sense of urgency to get important therapies to those who need them. In fact, many of them are former regulators themselves.
Working together, our regulatory consulting services empower you to maintain control of your pathway and stay ahead of any compliance risks. With practical interpretation, we help you understand how guidelines around the world apply to you – including in expanding markets like China.
Our services include:
- Regulatory Strategy & Development Planning
- Regulatory / GMP Compliance
- Regulatory Partnerships
- Clinical Trial Regulatory Services
Meet Our People
With Parexel, a seasoned advisor is always close by and ready to guide your molecule to market, including strategic compliance experts and former FDA, EMA and NMPA employees. Click to meet some of our team.
Visit our COVID-19 Resource Center
Get the latest COVID-19 news, translated guidance information and expert interpretations from our former regulators.
Meet our experts
Our 1000+ consulting team includes ~100 former regulators, HTA assessors and inspectors.
Video: Beginning with the end in mind
Regenerative Medicine versus Regenerative Medicine Therapies versus Regenerative Advanced Therapy, What is the Difference?
Read Now
Points to Consider When Referencing a Master File in FDA Regulatory Submissions (IND, BLA, NDA)
Read Now
Points to Consider for Establishing Biotechnological/Biological Product Comparability
Read Now
Benefits of Identifying Critical Quality Attributes, and Correlating the CQAs with Clinical Outcomes for Biologic Products
Read Now
FDA & EMA Joint Report on Early Access Pathways
Read Now
A Long and Winding Road for Transdermal Products – FDA Has It Covered
Read Now
Demystifying FDA’s KASA Initiative… and how it aims to improve drug product, facility, and corporate quality monitoring
Read Now
Facilities and the 356h Form - Ensuring All Relevant Manufacturing Establishments are Appropriately Identified in FDA Drug Applications
Read Now
Biosimilars in China
Read Now
Rescuing Product Approvals from Data Integrity Issues
Read Now
SEE FULL CONTENT STREAM
Regenerative Medicine versus Regenerative Medicine Therapies versus Regenerative Advanced Therapy, What is the Difference?
Read Now
Points to Consider When Referencing a Master File in FDA Regulatory Submissions (IND, BLA, NDA)
Read Now
Points to Consider for Establishing Biotechnological/Biological Product Comparability
Read Now
Benefits of Identifying Critical Quality Attributes, and Correlating the CQAs with Clinical Outcomes for Biologic Products
Read Now
FDA & EMA Joint Report on Early Access Pathways
Read Now
A Long and Winding Road for Transdermal Products – FDA Has It Covered
Read Now
Demystifying FDA’s KASA Initiative… and how it aims to improve drug product, facility, and corporate quality monitoring
Read Now
Facilities and the 356h Form - Ensuring All Relevant Manufacturing Establishments are Appropriately Identified in FDA Drug Applications
Read Now
Biosimilars in China
Read Now
Rescuing Product Approvals from Data Integrity Issues
Read Now
Commercializing Gene and Cellular Therapy
Read Now
Impact of MDR, Article 117 medicinal products with an integral medical device
Read Now
Critical CGMP Compliance Risks Go Beyond The CEO and The Park Doctrine
Read Now
New Post-Market Surveillance Requirements (PMS) for all Medical Device Manufacturers
Read Now
Tips from FDA – Put Design of Experiments to Use in Drug Applications
Read Now
Criticality of Institutional Biosafety Committee for Clinical Studies of Cell and Gene Therapy Products
Read Now
What you need to know about FDA’s NEW draft Drug Master Files Guidance for Industry
Read Now
Further Limits on The Use of Guidance for Enforcement – How Will FDA React?
Read Now
Can FDA Disperse the Perfect Storm Forming Around Poor Pharmaceutical Quality?
Read Now
What FDA Considers When Assessing Microorganisms in Non-Sterile Drug Products
Read Now
Advice for Handling Potentially Mutagenic Impurities in Regulatory Submissions
Read Now
PAI Objectives Remain the Same, However Important Updates are Included
Read Now
When There Is No Guidance – Navigating Regulatory Meetings With FDA
Read Now
FDA Needs To Know How 503B Compounders Work
Read Now
CBER Launches CATT to Facilitate Innovation
Read Now
RIM Blog Series – Part 4: The Special Relationship Between Product and Process Data
Read Now
Heart Failure Trial Endpoints: Public Feedback on the Recent FDA Draft Guidance
Read Now
New Zealand Consultation on Proposed Warning Statements for Allergens in Medicines
Read Now
All EU Members Have Now Joined!
Read Now
RIM Blog Series - Part 3: Critical Features for a Successful RIM Platform
Read Now
Former FDA expert provides valuable advice on INTERACT programs for CBER products
Read Now
English Requirement for FDA GMP Documents
Read Now
Bispecific Antibody Development Program Guidance
Read Now
The State of Germline Gene Editing. What We Don’t Know!
Read Now
Key Questions to Consider When Licensing Cell & Gene Therapy Products
Read Now
Q&A: Developing and Labeling of In-vitro Companion Diagnostic Devices for Oncology Products
Read Now
Root Cause: Why does Regulatory Approval Not Always Equate to Commercial Success?
Read Now
How New India Clinical Trial Regulations Will Improve Drug Development
Read Now
Good Tissue Practices (GTP): A Lesser-Known GxP
Read Now
FDA Publishes Guidances Aimed at More Inclusive Eligibility Criteria for Cancer Clinical Trials
Read Now
FDA Releases a Biopharmaceutical Naming Update
Read Now
FDA Compliance: When Does Electronic Data become a cGMP Record?
Read Now
Four Strategies for Capitalizing on China’s New Generic Drug “4+7” Bulk-Buying Rules
Read Now
Regulatory Pathway for New Drug Importation into China
Read Now
New Zealand Draft Therapeutics Product Bill: Are You Prepared?
Read Now
Qualification as a Step Toward Assay Validation for CBER Regulated Cell and Gene Therapy Products
Read Now
A Guide to a No Deal BREXIT
Read Now
Falsified medicine directive EU
Read Now
How to Successfully Obtain Breakthrough Device Designation
Read Now
A Harmonized Approach to Data Integrity
Read Now
FDA Accelerates Initiatives to Modernize and Strengthen 510(k) Program
Read Now
Points to Consider for Manufacturing Biologics at the Clinical Site
Read Now
FDA Publishes Draft Guidance - Labeling for Human Prescription Drug and Biological Products
Read Now
Updates on Regenerative Medicine Advanced Therapy (RMAT) Designations
Read Now
FDA Publishes Draft Guidance- Rare Diseases: Common Issues in Drug Development
Read Now
Gene Therapy, the Cure and the Reality
Read Now
Leverage regulatory reform in China, but mitigate the risks
Read Now
Points to Consider When Mitigating Biopharmaceutical Virus Risk
Read Now
Points to Consider When Designing a Biologics Manufacturing Facility, Planning for Success Early On!
Read Now
FDA Publishes Draft Noncirrhotic Non-alcoholic Steatohepatitis (NASH) With Liver Fibrosis Guidance
Read Now
FDA Compliance Deadline for Stem Cell Clinics Offering Unapproved Products to Public
Read Now
Navigating the recent FDA Guidances for Industry: Generic Drugs and Shared System REMS
Read Now
How to Right-Size Quality and CGMP Compliance Investments
Read Now
A Perspective on GMPs for Cellular Therapy Commercialization
Read Now
Four trends that could shape the future of advanced therapy products
Read Now
One step closer to a refined US Biosimilar Landscape
Read Now
FDA Releases Draft Guidance on CMC for Gene Therapies
Read Now
Join Us At RAPS - Booth #339 in Vancouver, BC - Oct 1st and 2nd
Read Now
MHLW Announces Deadline for Submitting “SAKIGAKE” Designation
Read Now